The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers
NCT ID: NCT00985933
Last Updated: 2011-05-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
20 participants
INTERVENTIONAL
2010-02-28
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
NCT01795339
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
NCT04602221
A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine
NCT05451095
Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury
NCT06337994
The Effect of Acetylcholine on Memory and Attention
NCT00001977
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
180 mg of AZD8529
AZD8529
6 capsules by mouth 1 time 12 to 24 prior to assessments
Placebo to match AZD8529
6 capsules by mouth 1 time 12 to 24 hours prior to assessments
2
50 mg AD8529
AZD8529
6 capsules by mouth 1 time 12 to 24 prior to assessments
Placebo to match AZD8529
6 capsules by mouth 1 time 12 to 24 hours prior to assessments
3
Placebo
AZD8529
6 capsules by mouth 1 time 12 to 24 prior to assessments
Placebo to match AZD8529
6 capsules by mouth 1 time 12 to 24 hours prior to assessments
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD8529
6 capsules by mouth 1 time 12 to 24 prior to assessments
Placebo to match AZD8529
6 capsules by mouth 1 time 12 to 24 hours prior to assessments
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 12th grade education or equivalent
* Able to read and write English as primary language
Exclusion Criteria
* Substance abuse or dependence
* History of claustrophobia
21 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Krystal
Role: PRINCIPAL_INVESTIGATOR
Chair, Department of PsychiatryYale University School of MedicineChief of Psychiatry, Yale-New Haven Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D2285M00015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.